ARS Pharmaceuticals, Inc (NASDAQ:SPRY) — Market Cap & Net Worth
Market Cap & Net Worth: ARS Pharmaceuticals, Inc (SPRY)
ARS Pharmaceuticals, Inc (NASDAQ:SPRY) has a market capitalization of $509.41 Million ($509.41 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11943 globally and #3011 in its home market, demonstrating a -14.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ARS Pharmaceuticals, Inc's stock price $5.13 by its total outstanding shares 99300658 (99.30 Million). See SPRY capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
ARS Pharmaceuticals, Inc Market Cap History: 2020 to 2026
ARS Pharmaceuticals, Inc's market capitalization history from 2020 to 2026. Data shows change from $4.60 Billion to $509.41 Million (-24.42% CAGR).
Index Memberships
ARS Pharmaceuticals, Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.02% | #327 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1189 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.03% | #184 of 263 |
Weight: ARS Pharmaceuticals, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ARS Pharmaceuticals, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ARS Pharmaceuticals, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.73x
ARS Pharmaceuticals, Inc's market cap is 13.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.60 Billion | $17.84 Million | -$1.06 Million | 258.01x | N/A |
| 2021 | $661.34 Million | $5.51 Million | -$20.24 Million | 120.11x | N/A |
| 2022 | $847.03 Million | $1.32 Million | -$34.68 Million | 643.64x | N/A |
| 2023 | $544.17 Million | $30.00K | -$54.37 Million | 18138.92x | N/A |
| 2024 | $1.05 Billion | $89.15 Million | $8.00 Million | 11.75x | 130.99x |
| 2025 | $1.16 Billion | $84.28 Million | -$171.30 Million | 13.73x | N/A |
Competitor Companies of SPRY by Market Capitalization
Companies near ARS Pharmaceuticals, Inc in the global market cap rankings as of August 1, 2026.
Key companies related to ARS Pharmaceuticals, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
ARS Pharmaceuticals, Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, ARS Pharmaceuticals, Inc's market cap moved from $4.60 Billion to $ 509.41 Million, with a yearly change of -24.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $509.41 Million | -55.97% |
| 2025 | $1.16 Billion | +10.43% |
| 2024 | $1.05 Billion | +92.52% |
| 2023 | $544.17 Million | -35.76% |
| 2022 | $847.03 Million | +28.08% |
| 2021 | $661.34 Million | -85.63% |
| 2020 | $4.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of ARS Pharmaceuticals, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $509.41 Million USD |
| MoneyControl | $509.41 Million USD |
| MarketWatch | $509.41 Million USD |
| marketcap.company | $509.41 Million USD |
| Reuters | $509.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more